Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 25'th Feb 2026
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
04:05pm, Tuesday, 24'th Feb 2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
20,000 Shares in Revolution Medicines, Inc. $RVMD Purchased by Raiffeisen Bank International AG
06:12am, Monday, 23'rd Feb 2026
Raiffeisen Bank International AG acquired a new position in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to the company in its most recent disclosure with the Secu
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
04:05pm, Wednesday, 18'th Feb 2026
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push
02:05am, Monday, 16'th Feb 2026
Revolution Medicines (NASDAQ: RVMD) CEO Mark Goldsmith outlined the company's late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and offere
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
10:54am, Wednesday, 11'th Feb 2026
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of “Buy” from Brokerages
01:44am, Friday, 06'th Feb 2026
Shares of Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) have been given an average recommendation of "Buy" by the eighteen brokerages that are presently covering the firm, MarketBeat.com
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
04:05pm, Wednesday, 04'th Feb 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
11:55am, Tuesday, 27'th Jan 2026
Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.
Why Revolution Medicines Stock Plummeted by Almost 17% Today
07:16pm, Monday, 26'th Jan 2026
An apparent suitor has withdrawn from talks about acquiring the biotech, according to a media report. That's particularly discouraging, given that this business was apparently discussing a deal in the
Overlooked Stock: RVMD Sells After MRK Turns Away
04:30pm, Monday, 26'th Jan 2026
Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
06:01am, Monday, 26'th Jan 2026
Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.
Merck no longer in talks to buy Revolution Medicines, WSJ reports
03:27pm, Sunday, 25'th Jan 2026
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.
Merck No Longer in Talks to Buy Revolution Medicines
02:30pm, Sunday, 25'th Jan 2026
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
